Side-by-side · Research reference
CerebrolysinvsThymalin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED11/65 cited
BHuman-MechanisticAUTO-DRAFTED12/40 cited
Cerebrolysin
Porcine Brain-Derived Peptide Mix · Phase 3
14–21 daysTreatment course
IV infusion · 100-250 mL saline · Daily
Thymalin
Immune restorer · Russian peptide bioregulator
IM · Daily for 5–10 days · 1-2×/year
01Mechanism of Action
Parameter
Cerebrolysin
Thymalin
Primary target
Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation
T-cell precursors + thymus-axis maturation pathwayKhavinson 2002
Pathway
Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis
Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002
Downstream effect
Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery
Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002
Feedback intact?
Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis
—
Origin
Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids
Polypeptide fraction isolated from calf thymus extractKhavinson 2002
Antibody development
Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented
—
02Dosage Protocols
Parameter
Cerebrolysin
Thymalin
Standard dose (stroke)
30–50 mL / day IVStaszewski 2026Afridi 2026
Most trials use 30 mL in 100-250 mL saline over 30-60 min.
—
Lower dose (dementia)
10–20 mL / day IV or IMKhatkova 2026
Chronic neurodegenerative conditions; intermittent courses.
—
Duration
10–21 days (acute); intermittent courses (chronic)
Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.
5–10 day cycles, 1–2× per year
Timing (stroke)
Initiate within 12 hrs of symptom onset; up to 6 hrs optimal
Earlier initiation associated with better outcomes.
—
Adjunct to thrombectomy
30-50 mL daily × 10-14 days, starting day of EVT
Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.
—
Administration route
IV infusion (preferred) or IM injection
IV allows higher doses; IM used in outpatient/chronic settings.
—
Frequency
—
Once daily during cycle
Lower / starter dose
—
2.5 mg / day
Reconstitution
—
Saline or bacteriostatic water
Timing
—
Morning preferred
Half-life
—
Hours (estimated)
04Side Effects & Safety
Parameter
Cerebrolysin
Thymalin
Injection site reaction
Mild pain, erythema (IM route)
Mild erythema at IM site
Infusion reaction
Rare: flushing, transient hypotension during rapid IV
—
Agitation / Restlessness
Reported in <5% of patients; typically mild, self-limited
—
Serious adverse events
No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)
—
Hemorrhagic transformation
Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025
—
Mortality
No increase; meta-analysis RR 0.89 (0.68-1.18)
—
Allergic reaction
Rare; porcine origin theoretically immunogenic but clinically insignificant
Rare hypersensitivity to bovine-derived polypeptide
Seizure risk
Not elevated; safe in epilepsy populations
—
Autoimmune flare
—
Theoretical risk in active autoimmune disease
Long-term safety
—
Limited Western data
Pregnancy / OB
—
Avoid
Absolute Contraindications
Cerebrolysin
- ·Known hypersensitivity to porcine-derived products
- ·Active seizure disorder (relative — caution advised)
Thymalin
- ·Pregnancy / breastfeeding
- ·Bovine protein hypersensitivity
Relative Contraindications
Cerebrolysin
- ·Severe renal impairment (amino acid load — monitor)
- ·Pregnancy / lactation (insufficient safety data)
Thymalin
- ·Active autoimmune disease
- ·Concurrent immunosuppressant therapy
05Administration Protocol
Parameter
Cerebrolysin
Thymalin
1. Preparation (IV infusion)
Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.
Add 1–2 mL saline or bacteriostatic water per 10 mg vial.
2. Infusion rate
Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.
Intramuscular — deltoid or gluteal. Rotate sites.
3. IM injection (alternative)
For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.
Morning preferred during cycle.
4. Timing
Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.
Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.
5. Storage
Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.
23–25G, 25–38 mm IM needle.
6. Co-administration
Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.
—
06Stack Synergy
Cerebrolysin
+ Semax
ModerateCerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.
- Cerebrolysin
- 30 mL IV daily × 10-14 days
- Semax
- 300-600 mcg intranasal BID × 10-14 days
- Timing
- Concurrent during acute recovery phase
- Primary benefit
- Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI
+ BPC-157
Multi-pathwayCerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.
- Cerebrolysin
- 30-50 mL IV daily × 14 days
- BPC-157
- 250-500 mcg SQ daily × 14-28 days
- Timing
- Initiate both within 24-48 hrs of injury
- Primary benefit
- Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery
Thymalin
+ Thymosin α-1
ModerateThymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.
- Thymalin
- 5–10 mg IM · daily × 7 days
- Thymosin α-1
- 1.6 mg SQ · 2× weekly during the cycle
- Primary benefit
- Broad thymic restoration + targeted immune activation